Alpha 2.0
Login Register
» Articles » PMID: 36928172

Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

Overview
Journal J Pediatric Infect Dis Soc
Publisher Oxford University Press
Specialties Infectious Diseases
Pediatrics
Date 2023 Mar 17
PMID 36928172
Authors
Gilad Sherman
Gabriella S Lamb
Tanvi S Sharma
Elizabeth C Lloyd
Jerod Nagel
Nada N Dandam
Carlos R Oliveira
Hassan S Sheikha
Brenda I Anosike
Philip Lee
Surabhi B Vora
Karisma Patel
Paul K Sue
Beenish Rubbab
April M Yarbrough
Lakshmi Ganapathi
Mari M Nakamura
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.

Citing Articles

COVID-19 and MIS-C treatment in children-results from an international survey.

Dona D, Minotti C, Masini T, Penazzato M, van der Zalm M, Judd A Eur J Pediatr. 2023; 182(11):5087-5093.

PMID: 37672062 PMC: 10640428. DOI: 10.1007/s00431-023-05179-7.

Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae.

Habet V, Oliveira C Semin Respir Crit Care Med. 2023; 44(1):66-74.

PMID: 36646086 PMC: 9926930. DOI: 10.1055/s-0042-1759566.

References
1.
Chen P, Nirula A, Heller B, Gottlieb R, Boscia J, Morris J . SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):229-237. PMC: 7646625. DOI: 10.1056/NEJMoa2029849. View
2.
Gottlieb R, Nirula A, Chen P, Boscia J, Heller B, Morris J . Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021; 325(7):632-644. PMC: 7821080. DOI: 10.1001/jama.2021.0202. View
3.
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D . Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021; 385(21):1941-1950. DOI: 10.1056/NEJMoa2107934. View
4.
Rainwater-Lovett K, Redd J, Stewart M, Elias Calles N, Cluff T, Fang M . Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States. Open Forum Infect Dis. 2021; 8(8):ofab398. PMC: 8364980. DOI: 10.1093/ofid/ofab398. View
5.
Webb B, Buckel W, Vento T, Butler A, Grisel N, Brown S . Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis. 2021; 8(7):ofab331. PMC: 8314951. DOI: 10.1093/ofid/ofab331. View